PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Evolocumab - Lipid modification

PAD Profile : Evolocumab - Lipid modification Important

Keywords :
Dyslipidaemia, hyperlipidaemia, lipid modification, high cholesterol, raised cholesterol, Lipid regulating, PCSK9 Inhibitor, heterozygous familial hypercholesterolaemia, non-familial hypercholesterolaemia
Brand Names Include :
Repatha
Important Information :
Restricted to lipidologists only for heterozygous familial and non-familial hypercholesterolaemia.

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
05 October 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia in line with NICE TA394 (June 2016) Prescribing will be initiated and treatment continued by specialists with training in lipid management and notification of initiation and continuation of treatment will be via the Blueteq database. Evolocumab will be considered RED on the traffic light system

Associated BNF Codes

02. Cardiovascular System
02.12.00. Lipid-regulating drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More